Dr David Dodwell
BSc, MD, FRCP, FRCR
Senior Clinical Research Fellow
I am a senior breast oncologist based in Leeds with a number of research and governance activities. I am the lead oncologist on the Sloane, NHS screening & national HQIP breast cancer audits.
I am a senior clinical research fellow to the EBCTCG and a member of steering groups for 12 ongoing UK trials in breast cancer. I sit on the trial management committees for 3 trials.
I am UK lead for the SACT project (UK chemotherapy database) and chair the clinical group, which provides input and advice to this project to examine the safety, efficacy and cost-effectiveness of chemotherapy used in England.
Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality.
Kerr AJ. et al, (2022), Cancer Treat Rev, 105
Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials.
Early Breast Cancer Trialists’ Collaborative group (EBCTCG) None., (2021), Lancet Oncol, 22, 1139 - 1150
Breast tumour volume and blood flow measured by MRI after one cycle of epirubicin and cyclophosphamide-based neoadjuvant chemotherapy as predictors of pathological response.
Stevens W. et al, (2021), Br J Radiol
Locoregional Therapy for the Primary Tumour in Women with a De Novo Diagnosis of Metastatic Breast Cancer
Miller K. et al, (2021), Current Breast Cancer Reports
Treatment variation in early breast cancer in the UK.
Dodwell D. et al, (2020), BMJ, 371